- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Product delays thwart $40M Roche purchase
March 12, 2011
J.K. WallDelays getting new diabetes meters into the U.S. market appear to have tripped up Roche Diagnostics Corp. on its way to acquiring
a key software vendor.
MorePurdue case highlights costs of defending intellectual property
March 12, 2011
J.K. WallA complicated legal case about trade secrets points up a down side to the success Indiana’s research universities have
had turning their research into revenue: Large legal bills can eat much of the money.
MoreLilly suffers another bruise from Novo
March 9, 2011
J.K. WallThe failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the
highly touted diabetes drug.
MoreLilly confident of FDA approval for Amyvid, Lechleiter says
March 9, 2011
Bloomberg NewsEli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify
plaque in the brain associated with Alzheimer’s disease.
MoreDow Chemical moves toward engineered corn patent
March 1, 2011
Associated PressDow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for
its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
MoreUPDATE: Bioanalytical researcher opening lab in Indianapolis
March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the
workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of
a partnership.
MoreLilly looks to double pipeline size again
February 23, 2011
J.K. WallIndianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to
60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this
alternative pipeline.
MoreLilly's master plan for downtown (real estate)
February 19, 2011
Cory SchoutenAs Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could
establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian
streets 135 years ago.
MoreLilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreStruggling Lilly turns to antidepressant Cymbalta for lift
February 5, 2011
Greg AndrewsCymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition
arrives in 2013.
MoreEndocyte again changes terms of public offering
February 4, 2011
IBJ Staff and Bloomberg NewsThe West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more
than previously announced, but at a lower price of $6 each.
MoreDow Agro's quarterly sales, profit climb
February 3, 2011
IBJ Staff and Associated PressIndianapolis-based Dow AgroSciences on Thursday reported record fourth-quarter revenue of $1.3 billion, up 19 percent from
the prior-year period.
MoreMarcadia may fetch up to $537 million in sale
February 2, 2011
J.K. WallThe December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for
the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes
medicines.
MoreMolecules are moneymakers for software firm Indigo BioSystems
January 29, 2011
Chris O'MalleyEli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
MoreMarketing firm VMS plans growth, new jobs
January 28, 2011
IBJ StaffEvent-planning powerhouse VMS Inc. plans to invest more than $1.5 million to expand its Indianapolis life sciences marketing
operation and create as many as 102 jobs over the next four years, state officials said Friday morning.
MoreLife sciences to drive Purdue's next decade of building
January 26, 2011
J.K. WallOver the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center,
launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life
and Health Sciences Quadrangle next to Discovery Park.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreDown on luck, Lilly finds comfort in pets
January 19, 2011
J.K. WallEli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
MoreEndocyte prices IPO stock
January 14, 2011
J.K. WallThe West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch
$80 million to $92 million.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreRoche back in court as partner looks to sell to competitor
January 12, 2011
J.K. WallRoche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving
word the company is speeding up plans to sell itself to Roche rival Alere Inc.
MoreDeal could give Lilly full diabetes deck
January 12, 2011
J.K. WallEli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy
that some consultants think is key to pharma companies’ futures.
MoreUPDATE: Analysts praise Lilly diabetes deal with Boehringer
January 11, 2011
J.K. WallThe deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with
five drugs and payments to be named later—but analysts and investors generally liked what they heard.
MoreAprimo sale may usher in 'new wave' of tech deals
January 8, 2011
Chris O'MalleyObservers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not
only among IT firms, but also among biotech companies here.
MoreRoche aims to prevent bidding war for software firm
January 7, 2011
J.K. WallThe Swiss company, which operates its North American business out of Indianapolis, filed a lawsuit late last month against
Virginia-based Medical Automation Systems Inc. for breaching the purchase agreement the companies signed back in October.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
liek the rest of America
These quaint,obsessed musings by the stalkers are certainly entertaining, but I'm trying to figure out what, if anything, all the yelping below has to do with Zak Brown.
It's evident that Moffett was pushing the right buttons and corporate America is now trying to squash him. He just wanted to withdraw the free pilot services provided to the company by the pilots to try and put some pressure on a company that has not been interested in negotiating a contract in over 5 years. The company does not provide a contract because not having one has saved them a bundle of money. Shame on any Republic pilots not standing behind their union leader just because things are getting tough, can you not see such strategic moves by the company as putting the last union president in a corporate position and into THEIR pocket. Do you really believe the last union president is so appalled at the attempts by Moffett, do you not remember his oppositions to the company? We stood behind him. It has been proven over and over again for thousands of years without fail, a man cannot serve two masters. Anyone that believes people vote contrary to their paycheck and livelihood deserve to be taken advantage of, the recent statements by the former union president are laughable as he denounces the current union president from his new corporate position. Have you ever seen a drafted sports player score points for his previous team, it cannot be done, he is not on the pilots side anymore, he gets his money a different way now than you and I do, and he should not be allowed to remain on the seniority list. A drafted player brings strength, credibility, tactical knowledge, and a strategic advantage to his NEW team, he would not be drafted or paid were it otherwise. We are all forced to choose only one side to play for and support, not doing so has many references in life such as insider trading and shaving points, all illegal for good reason. This basic fact is why corporate moguls, scientist, and engineers all sign non-discloser agreements and non-compete clauses, as protection in case they are lured into switching sides as our former union president has done. No NFL coach ever drafted a player so that both teams could benefit and better understand each other, they are recruited to win the game against that former team, period. Likewise the company does not recruit the former union president by accident or mutual understanding, its strategy. Don't confuse playing the game with good sportsman-like conduct in support of common business and prosperity goals, with the requirement to only play for one side. Good men we all love and favor fall subject to this manipulation, often without their knowledge, and it is not a betrayal of their friendship to oppose them when they switch sides. If we did not love and trust them, they would not have been chosen and lured to the other side in the first place. The deception by the drafted player is not made at a conscious level, it's just human nature and it's all about money and power which corrupts our ability to be objective and loyal to two masters. This is why our court system created the defense attorney, and why our military created counter intelligence. Its strategy and its propaganda, and it works, and that's why the "powers to be" manipulate the chess pieces by sometimes changing their colors. Some players know they are being manipulated when their color is changed, but it brings them more money and power so they do not care. The rest have good intentions but do not even realize they are being manipulated. This tactic is also known by another name, Divide and Conquer. In battle sending an imperfect message with an imperfect team is obviously not ideal, but it's still being sent by YOUR team, your union leader, a leader that has common goals and common rewards with you, they are the best, because we have elected them to do a job for us. If you are not backing Moffett but believing the spin by those that have recently switched sides, you are taking food out of your own mouth. Showing unity and backing an imperfect situation still results in taking just as much ground, it's about unity and bargaining power. It's not necessary to wait around for that perfect attack because it will never come, the company will spin and attempt to destroy anyone that gets in their way. Ultimately it's not about any specific attack anyway, ASAP or whatever it makes no difference, it is and always has been only about power. If this company cared about safety it would not build pairings with 8 hour overnights, come on, are you that naive? Besides, do you really think Hoffa cares, no, he got a call from corporate America and was squeezed into denouncing Moffett. If he didn't they would spin the safety card against him and the Teamsters National with implication for truckers, future contracts, insurance rates etc...saying something like the Teamsters use safety as a bargaining chip, blah blah blah... Do you really think any pilot is going to do something unsafe for the contract, absolutely not, the only ones threatening safety here is the company with reduced rest, fatigue, and poverty. Do you not find it odd that Hoffa and the Teamsters are opposing a Teamster president publicly? Would the Teamsters National not normally support and work with one of their own? Why did they not sit down and help him strategize, correct any mistakes, and charge ahead? Would the Teamsters National not normally support and leverage a contract for all those pilots that have been paying Teamster dues, isn't that why we have all been paying Teamster dues in the first place? I sure haven't been paying dues so that the Teamsters National could come along and write this kind of an article undercutting our union leader and our unity. Whose side is the Teamsters National really on, it's obviously not the Republic pilots side.
No matter what Moffatt does the company is going to spin it like he is the terrorist and brainwash people like you into believing it, wake up, back your players that are trying to change things for you and your livelihood. Where has Hoffa been for the last 6 years, except collecting our dues. Seriously, do you really think an FO going for upgrade, signed off by a checkairman ready for the upgrade, who then fails, is not even capable of returning as a First Officer.
whoa!